8-K: Nuvalent's Neladalkib Shows Positive Pivotal Data in ALK+ NSCLC

Nuvalent, Inc. announced positive topline pivotal data for its investigational ALK-selective inhibitor, neladalkib, in TKI pre-treated patients with advanced ALK-positive non-small cell lung cancer (NSCLC) from the ALKOVE-1 Phase 1/2 clinical trial.

Summary

• Neladalkib, an investigational ALK-selective inhibitor, showed positive topline pivotal data in TKI pre-treated patients with advanced ALK-positive NSCLC from the global ALKOVE-1 Phase 1/2 clinical trial.
• Preliminary data from the Phase 2 exploratory cohort for TKI-naive patients with advanced ALK-positive NSCLC from the ALKOVE-1 study were also reported.
• The recommended Phase 2 dose (RP2D) for neladalkib is 150 mg once daily (QD).
• As of August 29, 2025, 781 patients with ALK-positive solid tumors received neladalkib, with 656 advanced ALK-positive NSCLC patients treated at RP2D.
• In the pivotal primary analysis population of 253 TKI pre-treated patients, the objective response rate (ORR) was 31% (79/253) by blinded independent central review (BICR).
• For lorlatinib-naive TKI pre-treated patients (n=63), ORR was 46% (29/63).
• Patients with ALK G1202R mutation (n=47) showed an ORR of 68% (32/47).
• For patients with measurable CNS lesions (n=92), intracranial ORR (IC-ORR) was 32% (29/92).
• Preliminary data for 44 TKI-naive patients showed an ORR of 86% (38/44) and a complete response (CR) rate of 9% (4/44).
• In TKI-naive patients with measurable intracranial lesions (n=9), IC-ORR was 78% (7/9) and IC-CR rate was 44% (4/9).
• Neladalkib demonstrated a generally well-tolerated safety profile; most frequent treatment-emergent adverse events (TEAEs) occurring in ≥15% of patients were alanine aminotransferase increased (47%), aspartate aminotransferase increased (44%), constipation (28%), dysgeusia (23%), peripheral edema (18%), cough and nausea (16% each).
• Dose reductions due to TEAEs occurred in 17% of patients, and 5% of patients discontinued treatment due to TEAEs.

Sentiment

Score: 9

Explanation: The filing reports highly positive clinical trial data for neladalkib across multiple challenging patient populations, including those heavily pre-treated and with specific resistance mutations, as well as very promising preliminary data in TKI-naive patients. The safety profile is also reported as generally well-tolerated. This significantly de-risks the drug's development and indicates strong potential for future regulatory approval and commercial success.

Positives

• Positive topline pivotal data for neladalkib in TKI pre-treated advanced ALK-positive NSCLC.
• Activity observed across heavily pre-treated patient subsets, including those who received a median of 3 prior lines of therapy and 91% having received prior lorlatinib, for which no approved therapies have demonstrated activity after.
• High ORR of 68% in patients with the challenging ALK G1202R resistance mutation.
• Demonstrated intracranial activity with an IC-ORR of 32% in TKI pre-treated patients with measurable CNS lesions.
• Very encouraging preliminary ORR of 86% and IC-ORR of 78% in TKI-naive patients.
• Generally well-tolerated safety profile consistent with its ALK-selective, TRK-sparing design.
• Durability of response (DOR) was significant, with 76% of TKI pre-treated responders remaining in response for at least 6 months, and 53% for at least 18 months.

Negatives

• Objective response rate (ORR) of 31% in the overall TKI pre-treated population, while positive given the patient profile, is not exceptionally high compared to first-line treatments.
• High incidence of transaminase elevations (ALT increased 47%, AST increased 44%), although generally low-grade, transient, and reversible.
• 17% of patients required dose reductions due to TEAEs, and 5% discontinued treatment due to TEAEs.

Risks

• Risk that the Company may not fully enroll its clinical trials or that enrollment will take longer than expected.
• Unexpected concerns may arise from additional data, analysis, or results obtained during preclinical studies and clinical trials.
• Preliminary results of clinical trials may not be predictive of future results from the same or other trials.
• Results of earlier clinical trials may not be predictive of the results of later-stage clinical trials.
• Data from clinical trials may not be sufficient to support registration, potentially requiring additional studies or trials.
• Occurrence of adverse safety events.
• Risks that the FDA may not approve potential products on expected timelines, or at all.
• Risks of unexpected costs, delays, or other unexpected hurdles.
• Risks that the Company may not be able to nominate drug candidates from its discovery programs.
• Direct or indirect impact of public health emergencies or global geopolitical circumstances on clinical trials, strategy, and future operations.
• Timing and outcome of planned interactions with regulatory authorities and the ability to interact with such officials due to government shutdowns or other political circumstances.
• Risks related to obtaining, maintaining, and protecting intellectual property.

Future Outlook

The Company plans to discuss the topline pivotal data for TKI pre-treated ALK-positive NSCLC with the U.S. Food and Drug Administration (FDA) at a pre-New Drug Application (NDA) meeting. Detailed study results are planned for presentation at a future medical meeting. Global enrollment for TKI-naive patients is ongoing in ALKAZAR, the Company's Phase 3 randomized controlled trial of neladalkib versus alectinib.

Management Comments

• Neladalkib demonstrated a generally well-tolerated safety profile consistent with its ALK-selective, TRK-sparing design.

Industry Context

The ALK-positive NSCLC landscape is characterized by the development of increasingly potent ALK TKIs. However, resistance mutations, particularly G1202R, and CNS metastases remain significant challenges, especially after treatment with later-generation TKIs like lorlatinib. Neladalkib's demonstrated activity in heavily pre-treated patients, including those with G1202R mutations and prior lorlatinib exposure, positions it as a potential critical option for patients who have exhausted existing therapies. Its preliminary efficacy in TKI-naive patients also suggests potential for earlier lines of treatment, competing with established drugs like alectinib.

Comparison to Industry Standards

• Neladalkib demonstrated activity in patients who had received a median of 3 prior lines of therapy, with 91% having received prior lorlatinib, an area where no approved therapies have demonstrated activity.
• The ORR of 68% in patients with the ALK G1202R resistance mutation is notable, as this mutation is a key driver of disease progression and often difficult to treat with existing ALK TKIs.
• The intracranial ORR (IC-ORR) of 32% in TKI pre-treated patients with active CNS disease at baseline, and 63% in lorlatinib-naive TKI pre-treated patients with measurable CNS lesions, indicates strong CNS penetration and activity, which is crucial given the high incidence of brain metastases in ALK-positive NSCLC.
• The preliminary ORR of 86% in TKI-naive patients is comparable to or potentially better than some currently approved first-line ALK TKIs, such as alectinib (which is the comparator in the ongoing ALKAZAR Phase 3 trial).

Stakeholder Impact

• Shareholders: Highly positive clinical data could lead to increased investor confidence and potential share price appreciation due to reduced development risk and increased market potential for neladalkib.
• Patients: Offers a promising new treatment option, especially for those with advanced ALK-positive NSCLC who have failed multiple prior therapies, including lorlatinib, or have challenging resistance mutations and CNS metastases.
• Healthcare Providers: Provides a new therapeutic tool for managing complex ALK-positive NSCLC cases.
• Competitors: Poses a competitive threat to existing ALK TKI manufacturers, particularly if neladalkib demonstrates superior efficacy or safety in specific patient populations or in earlier lines of therapy.

Next Steps

• Discuss topline pivotal data for TKI pre-treated ALK-positive NSCLC with the U.S. Food and Drug Administration (FDA) at a pre-New Drug Application (NDA) meeting.
• Present detailed study results at a future medical meeting.
• Continue global enrollment of TKI-naive patients in ALKAZAR, the Company's Phase 3 randomized controlled trial of neladalkib versus alectinib.

Key Dates

Recommendation

The reported positive topline pivotal data for neladalkib in a highly challenging, heavily pre-treated ALK-positive NSCLC patient population, coupled with very strong preliminary data in TKI-naive patients, represents a significant de-risking event for Nuvalent. The drug's efficacy in patients who have failed prior lorlatinib and those with G1202R mutations addresses a critical unmet medical need. The favorable safety profile further strengthens its market potential. These results strongly suggest a high probability of regulatory success and future commercialization, making Nuvalent an attractive investment.

Keywords

Nuvalent, neladalkib, ALK-positive NSCLC, non-small cell lung cancer, ALK inhibitor, TKI, tyrosine kinase inhibitor, ALKOVE-1, ALKAZAR, clinical trial, Phase 1/2, Phase 3, oncology, cancer treatment, G1202R mutation, CNS metastases, FDA, drug development